Key Drivers
- Profitability Strength
- Liquidity Softening
- Premium Multiple
AIAI Summary
Thermo Fisher (TMO) is no longer a simple high-quality compounder but a “show-me” story where the investment case now hinges on proving durable margin recovery and stronger cash conversion amid integration risk from Clario, tighter liquidity, and a valuation that still leaves little room for execution misses.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Profitability Strength
- •Liquidity Softening
- •Premium Multiple
Thermo Fisher shows strong profitability and cash generation, but rising leverage, weaker liquidity, and a premium valuation mean investors are paying for continued execution.
Price Behavior
Key Price Behavior Insights:
- •Lower highs/lows
- •Failed rebounds
- •Near support test
TMO has shifted from an uptrend to a clear downtrend over the last month, breaking below $513-$526 and now testing $438.34 with rebounds repeatedly capped in the $466-$475 zone.
Sharp breakdown below $513-$526 on 2026-04-23, with repeated rebound failures in the mid-$460s to mid-$470s
Sentiment & News
Key News Insights:
- •Strong earnings
- •Rich valuation
- •Mixed ownership
Thermo Fisher delivered strong Q1 results and steady business trends, but persistent valuation concerns, uneven segment/geographic signals, and mixed investor sentiment kept the stock under pressure.
The news is modestly negative for the stock near term, as solid fundamentals are being offset by a pricey valuation and cautious market reaction
Similar Companies in Healthcare
Other companies in the same sector with AI ratings